← Leaderboards
Maksim Mamonkin
March Biosciences Inc
$1,562,155
Attributed
$3,124,310
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2024–25$2.5M$1.9M$1.3M$625K$0
'24
'25
Funding mix
By agency
NIH$3,124,310 · 2
By mechanism
R44$3,124,310 · 2
Top collaborators
- Sarah Marie Hein3 shared
Most similar at March Biosciences Inc
Same institution · by research overlap
- Sarah Marie Hein$1,562,155
Others in their field
Other Rising Stars on “Manufacture”
- Cyrus Wadia · Activate Global, Inc.$31,489,493
- Tim A Bertram · Wake Forest University School Of Medicine$30,163,580
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Kevin Saunders · Duke University$18,106,404
- Suma Babu · Massachusetts General Hospital$17,050,216
- Sabrina Paganoni · Massachusetts General Hospital$17,050,216
Research focus
ManufactureProductionDesignMalignant NeoplasmsNovel TherapeuticsPhase 1 StudyCollegeAntigensInfusion ProceduresMalignant - DescriptorManufacturing ProcessMedicineBiological SciencesChimeric Antigen Receptor T CellsAccelerationCell TherapyCancer CellCar T Cell TherapyEngineeringFitnessLicensingCellsChimeric Antigen ReceptorPrognosis
Grant awards (3)
A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma$1,124,607
R44 · FY2025 · CA
Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignancies$986,080
R44 · FY2025 · CA
Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignancies$1,013,623
R44 · FY2024 · CA